Erectile dysfunction (ED) is inconvenient enough on its own. The last thing you want is a pile-on of other inconveniences, like having to go to a doctor’s office for a diagnosis and prescription — and ...
Hims & Hers Health's stock has surged 205% since my last 'Buy' rating, but its valuation is now stretched, prompting a downgrade to 'Hold'. Some risks include Amazon's aggressive telehealth entry and ...
WASHINGTON — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as ...
In today's Pharmalittle roundup, we're reading about FDA targeting Hims & Hers, AstraZeneca halting U.K. investment, and much ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback